{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:48:16Z","timestamp":1794667696000,"version":"4.9.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/K015346\/1"],"award-info":[{"award-number":["MR\/K015346\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/V012509\/1"],"award-info":[{"award-number":["MR\/V012509\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001922","name":"DH | NIHR | Efficacy and Mechanism Evaluation Programme","doi-asserted-by":"publisher","award":["131575"],"award-info":[{"award-number":["131575"]}],"id":[{"id":"10.13039\/501100001922","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"DH | National Institute for Health Research","doi-asserted-by":"publisher","award":["Barts Biomedical Research Centre"],"award-info":[{"award-number":["Barts Biomedical Research Centre"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Approximately 40% of patients with rheumatoid arthritis do not respond to individual biologic therapies, while biomarkers predictive of treatment response are lacking. Here we analyse RNA-sequencing (RNA-Seq) of pre-treatment synovial tissue from the biopsy-based, precision-medicine STRAP trial (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009208), to identify gene response signatures to the randomised therapies: etanercept (TNF-inhibitor), tocilizumab (interleukin-6 receptor inhibitor) and rituximab (anti-CD20 B-cell depleting antibody). Machine learning models applied to RNA-Seq predict clinical response to etanercept, tocilizumab and rituximab at the 16-week primary endpoint with area under receiver operating characteristic curve (AUC) values of 0.763, 0.748 and 0.754 respectively (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200967-72) as determined by repeated nested cross-validation. Prediction models for tocilizumab and rituximab are validated in an independent cohort (R4RA): AUC 0.713 and 0.786 respectively (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200965-68). Predictive signatures are converted for use with a custom synovium-specific 524-gene nCounter panel and retested on synovial biopsy RNA from STRAP patients, demonstrating accurate prediction of treatment response (AUC 0.82-0.87). The converted models are combined into a unified clinical decision algorithm that has the potential to transform future clinical practice by assisting the selection of biologic therapies.\n                  <\/jats:p>","DOI":"10.1038\/s41467-025-60987-9","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T05:04:47Z","timestamp":1751432687000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Deep molecular profiling of synovial biopsies in the STRAP trial identifies signatures predictive of treatment response to biologic therapies in rheumatoid arthritis"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9365-5345","authenticated-orcid":false,"given":"Myles J.","family":"Lewis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4646-0849","authenticated-orcid":false,"given":"Cankut","family":"\u00c7ubuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9589-3005","authenticated-orcid":false,"given":"Anna E. A.","family":"Surace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7525-1558","authenticated-orcid":false,"given":"Elisabetta","family":"Sciacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8330-8048","authenticated-orcid":false,"given":"Rachel","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katriona","family":"Goldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Giorli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3757-3999","authenticated-orcid":false,"given":"Liliane","family":"Fossati-Jimack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4064-4014","authenticated-orcid":false,"given":"Alessandra","family":"Nerviani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6759-7521","authenticated-orcid":false,"given":"Felice","family":"Rivellese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1326-5051","authenticated-orcid":false,"given":"Costantino","family":"Pitzalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the STRAP collaborative group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edyta","family":"Jaworska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Bombardieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Humby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur G.","family":"Pratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Filer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagui","family":"Gendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Cauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Choy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Durez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya H.","family":"Buch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Gremese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan D.","family":"Ca\u00f1ete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Raizada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil D.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Jadon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Paolo","family":"Sainaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Stratton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Ehrenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim P.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaskar","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Gorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Zayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Rita","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cuervo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arti","family":"Mahto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Rawlings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chijioke","family":"Mosanya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Holroyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Maskall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Carlucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Thorburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Lliso-Ribera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Peel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Eurico","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent Meric","family":"de Bellefon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Githinji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Congia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Millar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirupam","family":"Purkayastha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakhi","family":"Seth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Celis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Hands-Greenwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Landew\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Perniola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Alivernini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Marcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasco","family":"Rom\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Galloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Chinoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sasieni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Barton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"60987_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen, J. S. et al. Rheumatoid arthritis. Nat. Rev. Dis. Prim. 4, 18001 (2018).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"60987_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41584-020-00541-7","volume":"17","author":"MH Buch","year":"2021","unstructured":"Buch, M. H., Eyre, S. & McGonagle, D. Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nat. Rev. Rheumatol. 17, 17\u201333 (2021).","journal-title":"Nat. Rev. Rheumatol."},{"key":"60987_CR3","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.mayocp.2017.05.009","volume":"92","author":"CA Wijbrandts","year":"2017","unstructured":"Wijbrandts, C. A. & Tak, P. P. Prediction of response to targeted treatment in rheumatoid arthritis. Mayo Clin. Proc. 92, 1129\u20131143 (2017).","journal-title":"Mayo Clin. Proc."},{"key":"60987_CR4","doi-asserted-by":"crossref","unstructured":"Wang, S. S., Lewis, M. J. & Pitzalis, C. DNA methylation signatures of response to conventional synthetic and biologic disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis. Biomedicines 11, 1987 (2023).","DOI":"10.3390\/biomedicines11071987"},{"key":"60987_CR5","doi-asserted-by":"publisher","first-page":"R90","DOI":"10.1186\/ar4555","volume":"16","author":"G Dennis Jr.","year":"2014","unstructured":"Dennis, G. Jr. et al. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Res. Ther. 16, R90 (2014).","journal-title":"Arthritis Res. Ther."},{"key":"60987_CR6","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.4049\/jimmunol.167.2.1072","volume":"167","author":"S Takemura","year":"2001","unstructured":"Takemura, S. et al. Lymphoid neogenesis in rheumatoid synovitis. J. Immunol. 167, 1072\u20131080 (2001).","journal-title":"J. Immunol."},{"key":"60987_CR7","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2013-203923","volume":"74","author":"IY Choi","year":"2015","unstructured":"Choi, I. Y. et al. MRP8\/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Ann. Rheum. Dis. 74, 499\u2013505 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"60987_CR8","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1002\/art.23902","volume":"58","author":"S Dass","year":"2008","unstructured":"Dass, S. et al. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum. 58, 2993\u20132999 (2008).","journal-title":"Arthritis Rheum."},{"key":"60987_CR9","doi-asserted-by":"publisher","first-page":"101ra192","DOI":"10.1126\/scitranslmed.3002432","volume":"3","author":"K Owczarczyk","year":"2011","unstructured":"Owczarczyk, K. et al. A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis. Sci. Transl. Med. 3, 101ra192 (2011).","journal-title":"Sci. Transl. Med."},{"key":"60987_CR10","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1136\/annrheumdis-2012-202435","volume":"73","author":"L Quartuccio","year":"2014","unstructured":"Quartuccio, L. et al. The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. Ann. Rheum. Dis. 73, 716\u2013721 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"60987_CR11","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1186\/ar3819","volume":"14","author":"HG Raterman","year":"2012","unstructured":"Raterman, H. G. et al. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res. Ther. 14, R95 (2012).","journal-title":"Arthritis Res. Ther."},{"key":"60987_CR12","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1136\/ard.2010.147199","volume":"70","author":"S Vosslamber","year":"2011","unstructured":"Vosslamber, S. et al. Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis. Ann. Rheum. Dis. 70, 1153\u20131159 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"60987_CR13","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1136\/annrheumdis-2011-201115","volume":"71","author":"VE Hogan","year":"2012","unstructured":"Hogan, V. E. et al. Pretreatment synovial transcriptional profile is associated with early and late clinical response in rheumatoid arthritis patients treated with rituximab. Ann. Rheum. Dis. 71, 1888\u20131894 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"60987_CR14","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s13075-016-1190-z","volume":"18","author":"J Sellam","year":"2016","unstructured":"Sellam, J. et al. Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. Arthritis Res. Ther. 18, 294 (2016).","journal-title":"Arthritis Res. Ther."},{"key":"60987_CR15","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1002\/art.38023","volume":"65","author":"J Sellam","year":"2013","unstructured":"Sellam, J. et al. CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 65, 2253\u20132261 (2013).","journal-title":"Arthritis Rheum."},{"key":"60987_CR16","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1093\/rheumatology\/keaa529","volume":"59","author":"B Nouri","year":"2020","unstructured":"Nouri, B., Nair, N. & Barton, A. Predicting treatment response to IL6R blockers in rheumatoid arthritis. Rheumatol. 59, 3603\u20133610 (2020).","journal-title":"Rheumatol."},{"key":"60987_CR17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","volume":"397","author":"F Humby","year":"2021","unstructured":"Humby, F. et al. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet 397, 305\u2013317 (2021).","journal-title":"Lancet"},{"key":"60987_CR18","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1016\/j.celrep.2019.07.091","volume":"28","author":"MJ Lewis","year":"2019","unstructured":"Lewis, M. J. et al. Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes. Cell Rep. 28, 2455\u20132470.e2455 (2019).","journal-title":"Cell Rep."},{"key":"60987_CR19","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/s41591-022-01789-0","volume":"28","author":"F Rivellese","year":"2022","unstructured":"Rivellese, F. et al. Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nat. Med. 28, 1256\u20131268 (2022).","journal-title":"Nat. Med."},{"key":"60987_CR20","doi-asserted-by":"publisher","first-page":"e648","DOI":"10.1016\/S2665-9913(23)00241-2","volume":"5","author":"F Rivellese","year":"2023","unstructured":"Rivellese, F. et al. Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials. Lancet Rheumatol. 5, e648\u2013e659 (2023).","journal-title":"Lancet Rheumatol."},{"key":"60987_CR21","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/s41590-019-0378-1","volume":"20","author":"F Zhang","year":"2019","unstructured":"Zhang, F. et al. Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat. Immunol. 20, 928\u2013942 (2019).","journal-title":"Nat. Immunol."},{"key":"60987_CR22","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41586-023-06708-y","volume":"623","author":"F Zhang","year":"2023","unstructured":"Zhang, F. et al. Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes. Nature 623, 616\u2013624 (2023).","journal-title":"Nature"},{"key":"60987_CR23","doi-asserted-by":"crossref","unstructured":"Cherlin, S. et al. Investigation of genetically regulated gene expression and response to treatment in rheumatoid arthritis highlights an association between IL18RAP expression and treatment response. Ann. Rheum. Dis. 79, 1446\u20131452 (2020).","DOI":"10.1136\/annrheumdis-2020-217204"},{"key":"60987_CR24","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1136\/annrheumdis-2018-214539","volume":"78","author":"F Humby","year":"2019","unstructured":"Humby, F. et al. Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. Ann. Rheum. Dis. 78, 761\u2013772 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"60987_CR25","doi-asserted-by":"publisher","first-page":"6519","DOI":"10.4049\/jimmunol.171.12.6519","volume":"171","author":"H Guan","year":"2003","unstructured":"Guan, H. et al. Neuronal repellent Slit2 inhibits dendritic cell migration and the development of immune responses. J. Immunol. 171, 6519\u20136526 (2003).","journal-title":"J. Immunol."},{"key":"60987_CR26","doi-asserted-by":"publisher","first-page":"R45","DOI":"10.1186\/ar2955","volume":"12","author":"AE Denk","year":"2010","unstructured":"Denk, A. E. et al. Slit3 inhibits Robo3-induced invasion of synovial fibroblasts in rheumatoid arthritis. Arthritis Res. Ther. 12, R45 (2010).","journal-title":"Arthritis Res. Ther."},{"key":"60987_CR27","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1136\/annrheumdis-2012-201978","volume":"72","author":"W Gao","year":"2013","unstructured":"Gao, W. et al. Notch signalling pathways mediate synovial angiogenesis in response to vascular endothelial growth factor and angiopoietin 2. Ann. Rheum. Dis. 72, 1080\u20131088 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"60987_CR28","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1101\/gad.14.11.1343","volume":"14","author":"LT Krebs","year":"2000","unstructured":"Krebs, L. T. et al. Notch signaling is essential for vascular morphogenesis in mice. Genes Dev. 14, 1343\u20131352 (2000).","journal-title":"Genes Dev."},{"key":"60987_CR29","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41586-020-2222-z","volume":"582","author":"K Wei","year":"2020","unstructured":"Wei, K. et al. Notch signalling drives synovial fibroblast identity and arthritis pathology. Nature 582, 259\u2013264 (2020).","journal-title":"Nature"},{"key":"60987_CR30","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1136\/annrheumdis-2019-215751","volume":"78","author":"G Lliso-Ribera","year":"2019","unstructured":"Lliso-Ribera, G. et al. Synovial tissue signatures enhance clinical classification and prognostic\/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC). Ann. Rheum. Dis. 78, 1642\u20131652 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"60987_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/bioadv\/vbad048","volume":"3","author":"MJ Lewis","year":"2023","unstructured":"Lewis, M. J. et al. nestedcv: an R package for fast implementation of nested cross-validation with embedded feature selection designed for transcriptomics and high-dimensional data. Bioinform. Adv. 3, vbad048 (2023).","journal-title":"Bioinform. Adv."},{"key":"60987_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-015-0129-6","volume":"8","author":"B Wallden","year":"2015","unstructured":"Wallden, B. et al. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Med. Genomics 8, 54 (2015).","journal-title":"BMC Med. Genomics"},{"key":"60987_CR33","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/s41591-020-0939-8","volume":"26","author":"S Alivernini","year":"2020","unstructured":"Alivernini, S. et al. Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis. Nat. Med. 26, 1295\u20131306 (2020).","journal-title":"Nat. Med."},{"key":"60987_CR34","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/art.1780351009","volume":"35","author":"BW Deleuran","year":"1992","unstructured":"Deleuran, B. W. et al. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha. Arthritis Rheum. 35, 1170\u20131178 (1992).","journal-title":"Arthritis Rheum."},{"key":"60987_CR35","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.clinthera.2018.04.016","volume":"40","author":"O Pala","year":"2018","unstructured":"Pala, O., Diaz, A., Blomberg, B. B. & Frasca, D. B Lymphocytes in rheumatoid arthritis and the effects of anti-TNF-\u03b1 agents on B lymphocytes: a review of the literature. Clin. Ther. 40, 1034\u20131045 (2018).","journal-title":"Clin. Ther."},{"key":"60987_CR36","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/0092-8674(95)90192-2","volume":"83","author":"M Grell","year":"1995","unstructured":"Grell, M. et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83, 793\u2013802 (1995).","journal-title":"Cell"},{"key":"60987_CR37","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3109\/03009742.2013.834964","volume":"43","author":"P Nereg\u00e5rd","year":"2014","unstructured":"Nereg\u00e5rd, P. et al. Etanercept decreases synovial expression of tumour necrosis factor-\u03b1 and lymphotoxin-\u03b1 in rheumatoid arthritis. Scand. J. Rheumatol. 43, 85\u201390 (2014).","journal-title":"Scand. J. Rheumatol."},{"key":"60987_CR38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/ard.53.1.39","volume":"53","author":"G Yanni","year":"1994","unstructured":"Yanni, G., Whelan, A., Feighery, C. & Bresnihan, B. Synovial tissue macrophages and joint erosion in rheumatoid arthritis. Ann. Rheum. Dis. 53, 39\u201344 (1994).","journal-title":"Ann. Rheum. Dis."},{"key":"60987_CR39","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1136\/ard.2007.080440","volume":"67","author":"CA Wijbrandts","year":"2008","unstructured":"Wijbrandts, C. A. et al. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium. Ann. Rheum. Dis. 67, 1139\u20131144 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"60987_CR40","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.3899\/jrheum.090348","volume":"36","author":"B Bresnihan","year":"2009","unstructured":"Bresnihan, B. et al. Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers. J. Rheumatol. 36, 1800\u20131802 (2009).","journal-title":"J. Rheumatol."},{"key":"60987_CR41","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nrrheum.2016.217","volume":"13","author":"M Bombardieri","year":"2017","unstructured":"Bombardieri, M., Lewis, M. & Pitzalis, C. Ectopic lymphoid neogenesis in rheumatic autoimmune diseases. Nat. Rev. Rheumatol. 13, 141\u2013154 (2017).","journal-title":"Nat. Rev. Rheumatol."},{"key":"60987_CR42","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1093\/rheumatology\/kev421","volume":"55","author":"BV Cuppen","year":"2016","unstructured":"Cuppen, B. V. et al. Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability. Rheumatology 55, 826\u2013839 (2016).","journal-title":"Rheumatology"},{"key":"60987_CR43","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1002\/art.30596","volume":"63","author":"P Lal","year":"2011","unstructured":"Lal, P. et al. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment. Arthritis Rheum. 63, 3681\u20133691 (2011).","journal-title":"Arthritis Rheum."},{"key":"60987_CR44","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/annrheumdis-2011-201117","volume":"72","author":"JD Isaacs","year":"2013","unstructured":"Isaacs, J. D. et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann. Rheum. Dis. 72, 329\u2013336 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"60987_CR45","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/rheumatology\/keaa393","volume":"60","author":"DS Courvoisier","year":"2021","unstructured":"Courvoisier, D. S. et al. The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. Rheumatology 60, 820\u2013828 (2021).","journal-title":"Rheumatology"},{"key":"60987_CR46","doi-asserted-by":"crossref","unstructured":"Pitzalis, C. Advances in targeted therapies (ATT) what\u2019s cooking in the academic\u2019s kitchen? 3TR (IMI). Semin. Arthritis Rheum. 64S, 152317 (2023).","DOI":"10.1016\/j.semarthrit.2023.152317"},{"key":"60987_CR47","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1136\/ard-2022-222784","volume":"82","author":"D Aletaha","year":"2023","unstructured":"Aletaha, D. et al. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. Ann. Rheum. Dis. 82, 773\u2013787 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"60987_CR48","first-page":"S-75","volume":"32","author":"JS Smolen","year":"2014","unstructured":"Smolen, J. S. & Aletaha, D. Scores for all seasons: SDAI and CDAI. Clin. Exp. Rheumatol. 32, S-75\u2013S-79 (2014).","journal-title":"Clin. Exp. Rheumatol."},{"key":"60987_CR49","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1093\/rheumatology\/keu413","volume":"54","author":"V Navarro-Comp\u00e1n","year":"2015","unstructured":"Navarro-Comp\u00e1n, V. et al. Relationship between disease activity indices and their individual components and radiographic progression in RA: a systematic literature review. Rheumatology 54, 994\u20131007 (2015).","journal-title":"Rheumatology"},{"key":"60987_CR50","doi-asserted-by":"crossref","unstructured":"Hensor, E. M. A. et al. Validity of a two-component imaging-derived disease activity score for improved assessment of synovitis in early rheumatoid arthritis. Rheumatology 58, 1400\u20131409 (2019).","DOI":"10.1093\/rheumatology\/kez049"},{"key":"60987_CR51","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41584-020-0491-4","volume":"16","author":"C Pitzalis","year":"2020","unstructured":"Pitzalis, C., Choy, E. H. S. & Buch, M. H. Transforming clinical trials in rheumatology: towards patient-centric precision medicine. Nat. Rev. Rheumatol. 16, 590\u2013599 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"60987_CR52","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1136\/annrheumdis-2013-204603","volume":"74","author":"S Kelly","year":"2015","unstructured":"Kelly, S. et al. Ultrasound-guided synovial biopsy: a safe, well-tolerated and reliable technique for obtaining high-quality synovial tissue from both large and small joints in early arthritis patients. Ann. Rheum. Dis. 74, 611\u2013617 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"60987_CR53","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 14, 417\u2013419 (2017).","journal-title":"Nat. Methods"},{"key":"60987_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"60987_CR55","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1093\/rheumatology\/keu163","volume":"53","author":"S Bugatti","year":"2014","unstructured":"Bugatti, S. et al. High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease. Rheumatology 53, 1886\u20131895 (2014).","journal-title":"Rheumatology"},{"key":"60987_CR56","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1365-2559.2006.02508.x","volume":"49","author":"V Krenn","year":"2006","unstructured":"Krenn, V. et al. Synovitis score: discrimination between chronic low-grade and high-grade synovitis. Histopathology 49, 358\u2013364 (2006).","journal-title":"Histopathology"},{"key":"60987_CR57","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/ni.2789","volume":"15","author":"S Li","year":"2014","unstructured":"Li, S. et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat. Immunol. 15, 195\u2013204 (2014).","journal-title":"Nat. Immunol."},{"key":"60987_CR58","doi-asserted-by":"publisher","first-page":"6059","DOI":"10.1158\/0008-5472.CAN-17-2705","volume":"78","author":"C Cubuk","year":"2018","unstructured":"Cubuk, C. et al. Gene expression integration into pathway modules reveals a Pan-cancer metabolic landscape. Cancer Res. 78, 6059\u20136072 (2018).","journal-title":"Cancer Res."},{"key":"60987_CR59","doi-asserted-by":"crossref","unstructured":"Micheroli, R. et al. Role of synovial fibroblast subsets across synovial pathotypes in rheumatoid arthritis: a deconvolution analysis. RMD Open 8, e001949 (2022).","DOI":"10.1136\/rmdopen-2021-001949"},{"key":"60987_CR60","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/nature13182","volume":"507","author":"FANTOM Consortium","year":"2014","unstructured":"FANTOM Consortium et al. A promoter-level mammalian expression atlas. Nature 507, 462\u2013470 (2014).","journal-title":"Nature"},{"key":"60987_CR61","doi-asserted-by":"publisher","first-page":"e28210","DOI":"10.1371\/journal.pone.0028210","volume":"6","author":"AC Haury","year":"2011","unstructured":"Haury, A. C., Gestraud, P. & Vert, J. P. The influence of feature selection methods on accuracy, stability and interpretability of molecular signatures. PLoS ONE 6, e28210 (2011).","journal-title":"PLoS ONE"},{"key":"60987_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-02892-y","volume":"9","author":"F Mizoguchi","year":"2018","unstructured":"Mizoguchi, F. et al. Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis. Nat. Commun. 9, 789 (2018).","journal-title":"Nat. Commun."},{"key":"60987_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02659-x","volume":"9","author":"W Stephenson","year":"2018","unstructured":"Stephenson, W. et al. Single-cell RNA-seq of rheumatoid arthritis synovial tissue using low-cost microfluidic instrumentation. Nat. Commun. 9, 791 (2018).","journal-title":"Nat. Commun."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60987-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60987-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60987-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T05:04:50Z","timestamp":1751432690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60987-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["60987"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-60987-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"12 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.P., M.J.L. and C.C. are inventors on a patent application (no. GB 2410224.6), submitted by Queen Mary University of London, that covers methods used to select treatments in RA. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5374"}}